Name: Ipamorelin
SKU: 095
Availability: InStock

Ipamorelin

As Low as: $36.30 /per vial

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and a highly selective growth hormone secretagogue (GHS). Unlike some other growth hormone-releasing peptides (GHRPs), Ipamorelin is unique due to its high specificity for the growth hormone secretagogue receptor (GHS-R), also known as the ghrelin receptor. This selectivity allows it to stimulate growth hormone (GH) release from the anterior pituitary gland without significantly impacting the secretion of other hormones such as cortisol, prolactin, or adrenocorticotropic hormone (ACTH), which are often co-released by less specific GHS compounds. This clean profile makes Ipamorelin a valuable tool for research requiring precise manipulation of GH levels.

$65.00 – $5,030.00

Submit Request

SKU: 095 Category:Lyophilized

Description

Quick Facts

Ipamorelin primarily acts by binding to the GHS-R in the pituitary gland, mimicking the action of the endogenous ligand ghrelin. This binding triggers a signaling cascade that stimulates the somatotroph cells to synthesize and release growth hormone. Its selective action ensures that the release of GH is more physiological and pulsatile, closely resembling the body’s natural GH secretion pattern. This controlled release profile is beneficial in research as it minimizes potential unwanted side effects associated with elevated levels of other hormones, allowing for more focused study on GH-specific outcomes.

Growth Hormone Dynamics: Used extensively to study the precise mechanisms of growth hormone release and its impact on various physiological systems.
Body Composition & Metabolism: Investigated for its potential role in modulating lean muscle mass, reducing fat accumulation, and improving overall metabolic efficiency, often in conjunction with GHRH analogues.
Tissue Repair & Recovery: Explored in studies concerning muscle recovery after injury or intense exercise, as well as general tissue regeneration, due to GH’s role in protein synthesis and cellular repair.
Bone Health: Research also delves into its potential influence on bone mineral density and bone formation processes.
Anti-Aging Research: Due to its ability to stimulate natural GH release without undesirable side effects on other hormones, it is a subject of interest in studies related to healthy aging and maintaining youthful physiological functions.

Why Choose Peptide Chains for Ipamorelin?

Peptide Chains provides high-purity Ipamorelin in bulk API quantities, essential for rigorous and specific research endeavors. Our Ipamorelin is supplied in a stable, lyophilized format, ensuring optimal integrity and ease of handling for precise experimental protocols. We are committed to stringent quality control, including comprehensive analytical testing, to guarantee the exceptional purity, potency, and batch-to-batch consistency required for reliable and reproducible results in studies focused on selective growth hormone modulation and its downstream anabolic and regenerative effects.

Additional information

Weight	0.05 lbs
Dimensions	10 × 15 × 5 in
Size	2mg, 5mg, 10mg
Vial Quantity	Order a Sample, 10, 20, 50, 100

Ipamorelin, the first selective growth hormone secretagogue

Abstract

The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6 (ECs) = 1.3+/-0.4nmol/l and Emax = 85+/-5% vs 2.2+/-0.3nmol/l and 100%). A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6 (ED50 = 80+/-42nmol/kg and Emax = 1545+/-250ng GH/ml vs 115+/-36nmol/kg and 1167+/-120ng GH/ml). In conscious swine, ipamorelin released GH with an ED50 = 2.3+/-0.03 nmol/kg and an Emax = 65+/-0.2 ng GH/ml plasma. Again, this was very similar to GHRP-6 (ED50 = 3.9+/-1.4 nmol/kg and Emax = 74+/-7ng GH/ml plasma). GHRP-2 displayed higher potency but lower efficacy (ED50 = 0.6 nmol/kg and Emax = 56+/-6 ng GH/ml plasma). The specificity for GH release was studied in swine. None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release. In conclusion, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.

Ipamorelin, the first selective growth hormone secretagogue

Introduction

Growth hormone (GH) has been used for treatingvarious types of growth disorders for a number of years.Following the availability of recombinant GH in 1985,the unlimited supply has made it possible to investigate themore general metabolic effects of GH. Currently, a numberof data suggests beneﬁts of using GH in the frail elderly,osteoporosis, in catabolic states and wasting conditions,e.g. following surgery (1, 2). Convincing effects followingGH treatment in obesity have also been reported (3).Somatotrophs in the anterior pituitary gland releaseGH in a pulsatile fashion under the regulation of twohypothalamic peptides: GH-releasing hormone (GHRH)and somatostatin.
GHRH stimulates GH synthesis andsecretion, while somatostatin inhibits GH release with-out affecting GH synthesis (4, 5). In addition, a thirdsystem, the GH-releasing peptide (GHRP) system alsoseems to be involved in the regulation of GH release (6,7). Over the past years a growing interest in GHRPs hasevolved. It has been suggested that this novel class of GHsecretagogues, including GHRP-6 (6) and MK-677 (8),offer an advantage compared with exogenously admin-istered GH, by increasing plasma GH levels in a morephysiologically relevant, pulsatile fashion (9).A number of GH secretagogues have proven efﬁca-cious in elevating plasma GH in animals, e.g. in rats(10), dogs (11) and swine (12). More recently, GHRP-2(13), GHRP-6 (14), hexarelin (15), and MK-677 (16)have also been shown to elevate plasma GH in humans.All of these GH secretagogues potently release GH and,in addition, prolactin (PRL) and cortisol, the latterprobably indirectly by stimulating adrenocorticotrophin(ACTH) (17, 18).
139 552–561 ISSN 0804-4643q1998 Society of the European Journal of Endocrinology
In the present study we describe the development of anovel series of GHRP receptor-active GH secretagogues.A prototype of this series, ipamorelin, releases GH withhigh potency and efﬁcacy without signiﬁcant effects onplasma ACTH or cortisol levels, compared with the mainendogenous GH releasing compound, GHRH. Conse-quently, ipamorelin is the most selective GHRP receptor-active GH secretagogue described.